Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2026)
Stoke Therapeutics (STOK) posted quarterly EBITDA Margin of 857.57% for Q1 2026, down 92772.0% year-over-year from N/an in Q1 2025, and up 80.43% quarter-over-quarter from 4382.24% in Q4 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' EBITDA Margin history runs 5 years deep, the most recent figure standing at 857.57% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 92772.0% year-over-year to 857.57%; the TTM figure through Mar 2026 stood at 577.46% (down 59749.0% YoY), while the FY2025 annual figure was 11.16%, up 26615.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 857.57%, up from 4382.24% in the prior quarter.
- The five-year high for EBITDA Margin was 70.15% in Q1 2025, with the low at 4382.24% in Q4 2025.
- The 5-year median for EBITDA Margin is 781.12% (2022), against an average of 870.53%.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin surged 99551 bps in 2024, then plunged 432187 bps in 2025.
- Stoke Therapeutics' EBITDA Margin stood at 831.58% in 2022, then dropped by 27 bps to 1055.89% in 2023, then jumped by 94 bps to 60.37% in 2024, then plunged by 7158 bps to 4382.24% in 2025, then soared by 80 bps to 857.57% in 2026.
- Business Quant data shows STOK's EBITDA Margin at 857.57% in Q1 2026, 4382.24% in Q4 2025, and 405.3% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.67 Bn | - | -701.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -701.65% |
| Mar 31, 2026 | -857.57% |
| Dec 31, 2025 | -4,382.24% |
| Sep 30, 2025 | -405.30% |
| Jun 30, 2025 | -197.58% |
| Mar 31, 2025 | 70.15% |
| Dec 31, 2024 | -60.37% |
| Sep 30, 2024 | -613.06% |
| Jun 30, 2024 | -607.37% |
| Mar 31, 2024 | -672.96% |
| Dec 31, 2023 | -1,055.89% |
| Sep 30, 2023 | -823.28% |
| Jun 30, 2023 | -1,340.67% |
| Mar 31, 2023 | -479.23% |
| Dec 31, 2022 | -831.58% |
| Sep 30, 2022 | -934.53% |
| Jun 30, 2022 | -781.12% |
| Mar 31, 2022 | -826.50% |